Background: It is still controversial whether carbapenem-resistant Acinetobacter baumannii (CRAB) is an independent risk factor for mortality. This study aimed to determine the risk factors and outcomes of patients with CRAB bacteremia, compared to those with carbapenem-susceptible A. baumannii (CSAB) bacteremia. Methods: This retrospective cohort study was conducted in Taipei Veterans General Hospital, Taiwan. Patients with bacteremia due to A. baumannii during June 2002 and December 2007 were included. Results: A total of 62 patients with CRAB and 164 with CSAB bacteremia were included. Among these patients, the independent risk factors for acquiring CRAB bacteremia were hematological malignancy [odds ratio (OR): 4.04; 95% confidence interval (CI): 1.29 e12.70; p Z 0.017], previous use of cefepime (OR: 2.60; 95% CI 1.11e6.08; p Z 0.028) and use of total parenteral nutrition (OR: 3.06; 95% CI 1.12e8.39; p Z 0.029). The patients with CRAB bacteremia had higher mortality rate than those with CSAB bacteremia. However, multivariate analysis showed that among patients with A. baumannii bacteremia, acquisition of CRAB by itself was not an independent risk factor for 14-day mortality. Instead, the independent factors Available online at www.sciencedirect.com j ourna l home pa ge: www.e-jmii.com
Introduction
Acinetobacter baumannii, the common nosocomial pathogen of ventilator-associated pneumonia and bloodstream infection, is characterized by rapid development of resistance to multiple classes of antimicrobials, including carbapenems. 1, 2 Carbapenems are usually the antimicrobial agents of choice for the treatment of serious infections caused by multidrug resistant A. baumannii. 3, 4 However, carbapenem-resistant A. baumannii (CRAB) isolates have been increasingly reported worldwide in recent years 1, 3, 5, 6 and are of great importance because there are limited treatment options for the infected patients, which may be associated with increased mortality. 7 However, it is still controversial whether CRAB itself confers a higher mortality, 8, 9 or the higher mortality in patients with CRAB infection is attributed to the inappropriate therapy or other host factors, such as underlying diseases or disease severity.
In this study, we aimed to determine the risk factors and outcome of patients with CRAB bacteremia, compared to those with carbapenem susceptible A. baumannii (CSAB) bacteremia.
Materials and methods

Study design and population
This retrospective cohort study was conducted in Taipei 
Data collection and definition
Clinical data or laboratory parameters were collected by a standard form, in which definitions had been predefined. The collected data included demographic characteristics, underlying conditions, use of invasive procedures, laboratory results, antimicrobial therapy and clinical outcome.
A. baumannii bacteremia was diagnosed if an isolate of A. baumannii from one or more blood cultures was accompanied by two or more of the following conditions: (1) fever (temperature > 38 C) or hypothermia (temperature < 36 C); (2) tachypnea (respiratory rate > 24 breaths/min); (3) tachycardia (pulse rate > 90 beats/min); (4) leukocytosis (white cell count > 12,000 cells/mm 3 ); or (5) leukopenia (white cell count < 4000 cells/mm 3 ). 8 When a patient had more than one bacteremic episode, only the first episode was included. The date of the first positive blood culture was considered the date of onset of bacteremia. The sources of bacteremia were defined as previously described by Chiang et al. 10 The severity of illness was assessed by using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score.
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Comorbidity was divided into several categories as follows: autoimmune diseases including rheumatoid arthritis, systemic lupus erythematous and seronegative spondyloarthropathy; and hematological malignancies including leukemia, lymphoma and multiple myeloma. Mechanical ventilation was defined as receiving ventilator within 30 days before onset of bacteremia. Use of steroids or previous antimicrobial agents was defined as those administered within 30 days before bacteremia onset. Neutropenia was defined as an absolute neutrophil count <500 cells/mm 3 . Septic shock was defined as sepsis associated with evidence of organ hypoperfusion, and either a systolic blood pressure of <90 or >30 mmHg less than baseline values, or a requirement for the use of vasopressor to maintain blood pressure. 12 Invasive procedures included central venous catheterization, catheter use for hemodialysis, Foley catheterization, total parenteral nutrition, and mechanical ventilation.
To analyze the impact of antimicrobial resistance on clinical outcome, the appropriateness of antimicrobial therapy was assessed. Appropriate antimicrobial therapy was defined if a patient received at least one antimicrobial agent (including ampicillin/sulbactam) to which A. baumannii was susceptible within 72 hours of blood culture collection; otherwise, the antimicrobial therapy was considered inappropriate. An exception was that monotherapy with aminoglycoside was considered as inappropriate. The 14-day mortality rate was used in the outcome analysis, which was defined as death within 2 weeks after the onset of bacteremia.
Phenotypic and genotypic identification of Acinetobacter isolates
Isolates recovered from blood culture were phenotypically identified by using the API ID 32GN system (bioMerieux, Marcy l'Etoile, France). Those identified as Acinetobacter calcoaceticuseA. baumannii complex were further analyzed to genomic species level. Genomic species of A. baumannii were identified by a multiplex polymerase chain reaction method, 13 and all the A. baumannii isolates were detected for the presence of the intrinsic bla OxA-51 -like gene by using a previously described PCR detection method. 14 
Antimicrobial susceptibility test
Antimicrobial susceptibility tests were performed by disk diffusion test. Minimum inhibitory concentration of carbapenems (imipenem and meropenem) for A. baumannii isolates were determined by using agar dilution test. All the tests were performed and the results were interpreted in accordance with the Clinical and Laboratory Standards Institute guidelines. 15 Interpretation breakpoints for imipenem or meropenem of 4 mg/L were considered as susceptible, 8 mg/L as intermediate resistant, and ! 16 mg/L as resistant. 15 Intermediate resistance was regarded as resistance in our study.
Statistical analysis
Categorical variables were compared using the c 2 test with Yates correction or Fisher's exact test. Continuous variables were analyzed using the two-sample t test. A p value < 0.05 was considered statistically significant. Significant variables in the univariate analysis were further analyzed by multivariate analysis. To assess the independent risk factors of the patients associated with the development of CRAB bacteremia and 14-day mortality of A. baumannii bacteremia, multivariate logistic regression analyses with Cox proportional hazard model were performed to control the effects of confounding factors. A survival curve was illustrated with the KaplaneMeier method. To compare the univariate survival distribution among CRAB and CSAB, a log-rank test was used. All statistical analyses were performed using SPSS for Windows version 18 (SPSS Inc. Chicago, IL, USA).
Results
Patient characteristics
A total of 226 patients with A. baumannii bacteremia were included in this study. Among these patients, 62 cases were caused by CRAB and 164 by CSAB. The characteristics of the patients with CRAB and CSAB are listed in Table 1 . The sex distribution was similar between both groups of patients (p Z 0.86). There was also no significant difference in mean age among patients with CRAB or CSAB (69.6 AE 15.8 vs. 68.5 AE 17.6 years, p Z 0.662). One hundred and forty-five patients stayed in the intensive care unit (ICU), including 49 (33.8%) with CRAB and 96 (66.2%) with CSAB.
Risks for acquisition of CRAB bacteremia
Compared to patients with CSAB bacteremia, results of the univariate analysis (Table 1) showed that a greater proportion of patients with CRAB bacteremia stayed in the ICU (79% vs. 58.5%, p Z 0.007), but the duration of ICU stay before bacteremia onset was similar in both groups (22. 
Antimicrobial susceptibility of isolates and patients' outcome
All except four of the isolates were resistant concomitantly to imipenem and meropenem. Two of these isolates were susceptible to imipenem but resistant to meropenem, and two other isolates were susceptible to meropenem but resistant to imipenem. The susceptibility pattern of other antibiotics for CRAB and CSAB are illustrated in Table 2 . The resistance rates of amikacin, ceftazidime, ciprofloxacin, cefepime and piperacillin/tazobactem were significantly higher in the CRAB than CSAB group. Therapy with inappropriate antimicrobial agents was more often observed in patients with CRAB bacteremia (80.6% vs. 51.2%, p < 0. 001). Carbapenem was empirically used in 34 (54.84%) and 70 (42.68%) patients with CRAB and CSAB bacteremia, respectively. The patients with CRAB bacteremia had a higher mortality rate than those with CSAB bacteremia, by survival analysis (Fig. 1, log- 
Prognostic factors of 14-day mortality in patients with A. baumannii bacteremia
In the univariate analysis (Table 3) , the factors associated with 14-day mortality were acquisition of CRAB (35.5% vs. 20.7%, p Z 0.034), APACHE score > 20 (35.2% vs. 6.2%, p < 0.001), shock (55.2% vs. 20.3%, p < 0.001), hematological malignancy (45.5% vs. 22.54%, p Z 0.035), and inappropriate antimicrobial therapy (30.6% vs. 16.3%, p Z 0.022). Multivariate analysis revealed that the independent factors associated with 14-day mortality were: APACHE >20 (OR: 6.33; 95% CI: 2.32e17.26; p < 0.001), 
Discussion
Some studies have compared the risk factors and outcomes of patients with CRAB and CSAB bacteremia. 8,12,16e18 However, some of these 8, 12, 17, 18 have not identified the causative Acinetobacter isolates to the genomic species level, therefore, they might have included patients infected with A. baumannii, Acinetobacter genomic species 3 or Acinetobacter genomic species 13TU, which are undifferentiated by phenotypic identification methods. 19, 20 Among these three Acinetobacter genomic species, A. baumannii is more frequently multidrug resistant, 14 and may possess higher pathogenicity. 21 Therefore, the carbapenem resistant and susceptible isolates could actually have belonged to different Acinetobacter species, which would severely complicate the comparison and compromise the conclusions. To the best of our knowledge, the present study is the largest to focus on patients with only A. baumannii bacteremia.
In our study with a large case number, confounding factors associated with patients' outcome could be adjusted. Although the patients with CRAB bacteremia had a higher 14-day mortality rate than those with CSAB bacteremia, we showed that patients with CRAB and CSAB bacteremia had many different characteristics. Compared to patients with CSAB bacteremia, those with CRAB bacteremia had higher prevalence of immunocompromised diseases and worse clinical condition before bacteremia, such as autoimmune diseases, hematological malignancies and shock episodes. They also had greater severity of illness at bacteremia onset, as indicated by higher APACHE II score and requirement for ICU care, and more frequently required the support of invasive procedures, such as TPN, mechanical ventilation, and use of central venous and femoral venous catheters for hemodialysis and Foley catheters. They had more often received broad-spectrum antimicrobial therapy, such as cefepime and piperacillin/ tazobactam before bacteremia onset. CRAB bacteremia more often originated from pneumonia and less from urinary tract infection. Furthermore, as the CRAB isolates were more often resistant to multiple classes of antimicrobial agents, the patients with CRAB bacteremia were more likely to receive inappropriate therapy. All the above characteristics found in patients with CRAB bacteremia were likely to affect the patients' outcome. Indeed, the multivariate analysis showed that CRAB by itself was not an independent factor of 14-day mortality in patients with A. baumannii bacteremia, but the disease severity and inappropriate therapy were.
As a result, the identification of patients at risk of acquisition of CRAB followed by prompt initiation of appropriate therapy is important for those with A. baumannii bacteremia. In our study, the multivariate analysis showed that patients who had hematological malignancies were more likely to acquire CRAB than CSAB. It has been suggested that acquisition of resistance might lead to a compromise in virulence and fitness of bacteria. 22 Therefore, CRAB was likely to be pathogenic in those patients who were more immunocompromised. Previous use of cefepime was also a risk factor for acquiring CRAB. It has been suggested that CRAB occurrence may be facilitated by the selection pressure of previous antimicrobial use. 23 The use of TPN was also a risk factor for CRAB bacteremia in our study. However, the role of TPN in the acquisition of CRAB was not clear. It remains to be investigated whether rich nutrients or the route by which TPN was given played a more important role in the infection. Figure 1 . Cumulative survival rate after episode of CRAB and CSAB bacteremia. The curve was illustrated with the KaplaneMeier method. The patients with CRAB bacteremia had higher mortality rate than those with CSAB bacteremia (log-rank test, p Z 0.015). CRAB Z carbapenem-resistant Acinetobacter baumannii; CSAB Z carbapenem-susceptible Acinetobacter baumannii.
Nevertheless, the results indicated that an early shift of TPN to alimentary feeding is important in the prevention of acquisition of CRAB. As expected, disease severity such as high APCHE II score and shock status were independently associated with poor prognosis in patients with A. baumannii bacteremia. 5, 12 Besides, inappropriate therapy was also independently associated with poor prognosis, despite A. baumannii being regarded as a low-pathogenicity pathogen. 8, 16 Previously, some studies have suggested that carbapenem resistance is itself associated with poor prognosis. 17 However, the appropriateness of the therapy is not considered in the analysis, which might be the real factor that contributes to the poor patients' outcome.
Although this study included a large number of patients with A. baumannii bacteremia, it had the inherent limitations of a retrospective study, including inconsistency of patient care, noncomparability of the patients' background, and variation in treatment, which might have confounded the analysis. To ensure consistency in data collection, a standard form was set up for the process. In addition, multivariate analysis was performed to identify independent factors of interest.
In conclusion, we showed that, among patients with A. baumannii bacteremia, the independent risk factors for CRAB bacteremia were underlying diseases with hematological malignancies, previous use of cefepime, and receiving TPN. The APACHE score > 20, shock and inappropriate antimicrobial therapy were independent risk factors for 14-day mortality among these patients. Carbapenem resistance itself was not a risk factor of A. baumannii mortality. Early identification of CRAB followed by prompt appropriate antimicrobial therapy, such as colistin or tigecycline, may improve patient outcome. 
